Literature DB >> 8874385

A novel in vitro assay for human angiogenesis.

K J Brown1, S F Maynes, A Bezos, D J Maguire, M D Ford, C R Parish.   

Abstract

Angiogenesis, the development of new blood vessels, is an important process in tissue development and wound healing but becomes pathologic when associated with solid tumor growth, proliferative retinopathies, and rheumatoid arthritis. To date, there has not been a physiologically relevant in vitro model for human angiogenesis that can be used to screen for enhancers and inhibitors of human angiogenesis and allow further investigation of this process. Initially, culture conditions were established for the induction of human angiogenesis in vitro using fragments of human placental blood vessel. Once the assay was validated, it was examined for its ability to detect known inhibitors and enhancers of angiogenesis. The role of endogenous acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) in the angiogenic response was also assessed by performing RT-PCR on both the parent vessel and microvessel outgrowths. In addition, neutralizing antibodies against the three growth factors were used to quantify the relative importance of each growth factor in the angiogenic response. A fragment of human placental blood vessel was embedded in a fibrin gel in microculture plates and was found to give rise to a complex network of microvessels during a period of 7 to 21 days in culture. The response did not require the addition of exogenous growth factors, and thus provides a convenient system for testing substances for their ability to stimulate or inhibit a human in vitro angiogenic response. The ability of the well known angiogenesis antagonist, hydrocortisone, in the presence and absence of heparin, and suramin to significantly inhibit the angiogenic response indicated that the model could be used as an efficient in vitro assay for screening inhibitors of human angiogenesis. The presence of mRNA for aFGF, bFGF, and three isoforms of VEGF, as well as their receptors, FGFR1, FGFR2, Flt-1, and KDR, in vessel outgrowths and the parent vessel, as identified by RT-PCR, strongly implicated aFGF, bFGF, and VEGF as having an important role in this neovascularization response. This was further confirmed by the ability of neutralizing antibodies to aFGF, bFGF, and VEGF to inhibit the angiogenic response to varying extent. Furthermore, the response could be enhanced by the addition of these growth factors in serum-starved cultures. Finally, a stimulatory effect was observed when matrigel was incorporated into the fibrin gel, which indicates that components of the extracellular matrix also play an important role in governing the strength of the angiogenic response. A physiologic angiogenic response relevant to wound healing can be generated by culturing fragments of human placental blood vessels in fibrin gels. The growth factors aFGF, bFGF, and VEGF were shown to play an important role in stimulating this spontaneous angiogenic response. This assay, which can be performed in microcultures, was also shown to be an excellent method for screening for potential inhibitors and enhancers of human angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874385

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  37 in total

Review 1.  Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.

Authors:  Bruce A Corliss; Mohammad S Azimi; Jennifer M Munson; Shayn M Peirce; Walter L Murfee
Journal:  Microcirculation       Date:  2016-02       Impact factor: 2.628

2.  Amphiphilic suramin dissolves Matrigel, causing an 'inhibition' artefact within in vitro angiogenesis assays.

Authors:  Natalie L Prigozhina; Andrew J Heisel; Jordan R Seldeen; Nicholas D P Cosford; Jeffrey H Price
Journal:  Int J Exp Pathol       Date:  2013-09-02       Impact factor: 1.925

Review 3.  In vitro models of angiogenesis.

Authors:  Areck A Ucuzian; Howard P Greisler
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 4.  A critical analysis of current in vitro and in vivo angiogenesis assays.

Authors:  Carolyn A Staton; Malcolm W R Reed; Nicola J Brown
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

Review 5.  Models for assessment of angiogenesis in gliomas.

Authors:  R H Goldbrunner; S Wagner; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

6.  Anti-Kaposi's sarcoma and antiangiogenic activities of sulfated dextrins.

Authors:  M Thornton; L Barkley; J C Mason; S Shaunak
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

7.  Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model.

Authors:  Shao-ping Nie; Xiao Wang; Shi-bin Qiao; Qiu-tang Zeng; Ju-quan Jiang; Xiao-qing Liu; Xiang-ming Zhu; Guo-xiang Cao; Chang-sheng Ma
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

8.  FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis.

Authors:  Abha Sahni; Alok A Khorana; Raymond B Baggs; Hu Peng; Charles W Francis
Journal:  Blood       Date:  2005-09-13       Impact factor: 22.113

9.  Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.

Authors:  Ji-Kun Li; Liang Yu; Yun Shen; Li-Sheng Zhou; Yi-Cheng Wang; Jian-Hai Zhang
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

Review 10.  Molecular mediators of angiogenesis.

Authors:  Areck A Ucuzian; Andrew A Gassman; Andrea T East; Howard P Greisler
Journal:  J Burn Care Res       Date:  2010 Jan-Feb       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.